Ernexa Therapeutics (ERNA) News Today $1.96 -0.02 (-1.01%) Closing price 07/11/2025 03:58 PM EasternExtended Trading$1.98 +0.02 (+0.82%) As of 07/11/2025 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERNA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Ernexa Therapeutics Regains Compliance with Nasdaq for Continued ...July 11 at 3:06 AM | nasdaq.comErnexa Therapeutics Regains Compliance with Nasdaq ... - MorningstarJuly 11 at 3:06 AM | morningstar.comMErnexa Therapeutics Regains Compliance with Nasdaq Listing RequirementsJuly 9, 2025 | globenewswire.comErnexa Therapeutics changes independent auditor to Haskell & WhiteJuly 8, 2025 | investing.comErnexa Therapeutics Expands Scientific Advisory Board as It Prepares for Clinical Trials in Ovarian Cancer and Autoimmune Disease - NasdaqJune 27, 2025 | nasdaq.comErnexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical DevelopmentJune 25, 2025 | globenewswire.comErnexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase AgreementJune 24, 2025 | globenewswire.comErnexa Therapeutics Announces 1-for-15 Reverse Stock SplitJune 10, 2025 | globenewswire.comErnexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025May 28, 2025 | globenewswire.comErnexa Therapeutics Stock Short Interest Report | NASDAQ:ERNA | BenzingaMay 23, 2025 | benzinga.comErnexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical OperationsMay 14, 2025 | globenewswire.comErnexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025April 29, 2025 | globenewswire.comErnexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025April 22, 2025 | globenewswire.comErnexa Therapeutics files to sell 10.44M shares of common stock for holdersApril 17, 2025 | markets.businessinsider.comErnexa Therapeutics Closes New Funding RoundApril 3, 2025 | globenewswire.comEterna changes name to Ernexa TherapeuticsMarch 27, 2025 | markets.businessinsider.comEterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune DiseaseMarch 25, 2025 | markets.businessinsider.comEterna hosts inaugural meeting of newly formed SABFebruary 26, 2025 | markets.businessinsider.comEterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy PipelineFebruary 26, 2025 | globenewswire.comEterna appoints Zeldis, Sather to scientific advisory boardJanuary 29, 2025 | markets.businessinsider.comEterna Therapeutics (NASDAQ:ERNA) Stock Quotes, Forecast and News SummaryJanuary 14, 2025 | benzinga.comEterna Announces Positive Preclinical Study Results On ERNA-101 In Ovarian Cancer; Stock Up 69%January 14, 2025 | markets.businessinsider.comEterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian CancerJanuary 14, 2025 | globenewswire.comEterna Therapeutics Appoints Dr. Elena Ratner To Board Of DirectorsJanuary 9, 2025 | markets.businessinsider.comEterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of DirectorsJanuary 9, 2025 | globenewswire.comGrowth Trends in the Induced Pluripotent Stem Cells (iPSCs) Market, 2024-2035: A Forecasted $5.6 Billion LandscapeJanuary 9, 2025 | uk.finance.yahoo.comEterna Therapeutics Inc Ordinary SharesDecember 5, 2024 | morningstar.comMEterna launches research to evaluate ERNA-101December 3, 2024 | markets.businessinsider.comEterna Therapeutics Authorized $1 Mln Share Buyback; Stock Up In Pre-marketNovember 25, 2024 | markets.businessinsider.comEterna Therapeutics Announces Up to $1 Million Stock Repurchase ProgramNovember 25, 2024 | markets.businessinsider.comEterna regains compliance with NasdaqNovember 14, 2024 | markets.businessinsider.comEterna Therapeutics Regains Compliance with NASDAQ for Continued ListingNovember 14, 2024 | globenewswire.comEterna files to sell 49.87M shares of common stock for holdersNovember 7, 2024 | markets.businessinsider.comEterna completes strategic financial restructuringOctober 31, 2024 | markets.businessinsider.comEterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term SuccessOctober 30, 2024 | globenewswire.comEterna, Factor announce license, collaboration agreementOctober 19, 2024 | finance.yahoo.comEterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare DiseasesOctober 17, 2024 | globenewswire.comCoeptis Therapeutics (NASDAQ:COEP) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comEterna Therapeutics Inc. (ERNA)September 18, 2024 | finance.yahoo.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory DiseasesMay 10, 2024 | globenewswire.comEterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory BoardMay 8, 2024 | globenewswire.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory DiseasesMay 7, 2024 | finance.yahoo.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M LocusMay 7, 2024 | finance.yahoo.comQ4 2023 Cognition Therapeutics Inc Earnings CallMarch 27, 2024 | finance.yahoo.comViking Therapeutics' experimental tablet helps reduce weight in small studyMarch 26, 2024 | msn.comERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023March 15, 2024 | investorplace.comEterna Therapeutics Stock (NASDAQ:ERNA) Dividends: History, Yield and DatesFebruary 23, 2024 | benzinga.comEterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of DirectorsFebruary 20, 2024 | finance.yahoo.comEterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of DirectorsFebruary 20, 2024 | globenewswire.comEterna Therapeutics files to sell 18.2M shares for holdersJanuary 12, 2024 | msn.com Get Ernexa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter. Email Address ERNA Media Mentions By Week ERNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ERNA News Sentiment▼0.370.99▲Average Medical News Sentiment ERNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ERNA Articles This Week▼50▲ERNA Articles Average Week Get Ernexa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANL News CUE News KRON News CRVO News ANVS News ATRA News AVTX News GANX News ALGS News APLT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ERNA) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ernexa Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ernexa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ERNA Stock Alerts